Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
NCT05287945Phase 2Recruiting
- Sponsor
- Oncorena AB
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of orellanine in renal cell carcinoma (RCC), sponsored by Oncorena AB. Started Aug 2023; status: recruiting.
02
Drugs
orellanine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05287945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287945.